Loading
A phase 3 trial of Sapablursen in myeloproliferative neoplasms, run by Ono Pharmaceutical Co., Ltd., now recruiting.
INTREPID: A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV) is a phase 3 interventional study registered as NCT07429266 by Ono Pharmaceutical Co., Ltd., with 250 participants planned, started 2026-05-25 and due to reach its primary completion in 2028-09. Interventions recorded: Sapablursen and Placebo.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Polycythaemia vera (PV), Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
Shares Deciphera Pharmaceuticals (Ono) and the tag pipeline.
Shares Polycythaemia vera (PV), Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
Shares Polycythaemia vera (PV), Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
Shares Deciphera Pharmaceuticals (Ono) and the tag pipeline.
Shares Polycythaemia vera (PV), Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
Shares Deciphera Pharmaceuticals (Ono) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/